- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06309147
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
A Double-Blind, Single Center, Randomized, Placebo-Controlled Study of BMS-984923 in Participants With Parkinson's Disease
Study Overview
Detailed Description
This double-blind placebo-controlled study will evaluate 28 days of twice daily dosing of BMS-984923 at two dose levels in comparison to placebo in participants with early Parkinson's disease.
This research study will assess the safety and tolerability of multiple doses of BMS-984923 for the treatment of early Parkinson's disease and investigate Dopamine transporter levels in the brain measured with single photon emission computed tomography as an early marker of therapeutic response to a treatment that targets synapse restoration.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Alexis Schuettke
- Phone Number: 919-668-2842
- Email: alexis.schuettke@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27701
- Recruiting
- Duke Clinical Research Institute
-
Contact:
- Alexis Schuettke
- Phone Number: 919-668-2842
- Email: alexis.schuettke@duke.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men or women between the ages of 50 and 80 years, inclusive at the time of screening.
- Clinical diagnosis of Parkinson's disease as defined by the United Kingdom Parkinson's disease (PD) Society Brain Bank Clinical Diagnostic Criteria and Movement Disorder Society Parkinson's disease Criteria (must meet both criteria); must include bradykinesia and responsiveness to levodopa.
- Maintenance on stable Parkinson's disease therapy for at least 28 days prior to Screening/Visit 1 through treatment period to Day 42, with demonstratable medication efficacy as assessed by the Investigator.
- Severity of Parkinson's disease symptoms assessed by Hoehn and Yahr Staging score ≤3.0 (assessed in the "ON" state).
- Maintenance on permitted stable non-Parkinson's disease therapy for at least 28 days prior to Day 1 through the treatment period to Day 42.
- Female participants of childbearing potential must have a negative urine pregnancy test at Screening and baseline, as well as be non-lactating and must agree to use a highly effective method of contraception during the study and for 30 days following last dose of study drug.
- Male participants must be sterile or sexually inactive or agree not to father a child during the study and for 1 month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male subjects must adopt a highly effective method of contraception
- Adequate visual, hearing, cognitive and physical ability and willingness to comply with study drug administration, scheduled visits, treatment plan, laboratory tests, and other study-related procedures to complete the study
- Institutional Review Board/Ethics Committee-approved consent form signed and dated by the participant
Exclusion Criteria:
- Diagnosis of secondary or atypical parkinsonism
- Severe or disabling fluctuations or dyskinesias that would, in the opinion of the Investigator, interfere with completion of the study
- Previous surgical procedure for Parkinson's disease (e.g. Duopa, deep brain stimulation)
- Clinically significant cognitive impairment with a Montreal Cognitive Assessment score <18
- Has a history or current evidence of long QT syndrome
- Has bradycardia or tachycardia on the electrocardiogram (ECG) at Screening
- Clinical or laboratory findings consistent with another primary neurodegenerative disease or cognitive disorder other than Parkinson's disease, including but not limited to, frontotemporal lobar disease, Huntington's disease, progressive supranuclear palsy, multisystem atrophy, Jacob-Creutzfeld Disease, Down's syndrome, amyotrophic lateral sclerosis, seizure disorder, or other infectious, metabolic or systemic disease affecting the central nervous system including but not limited to, syphilis, present hypothyroidism, present vitamin B12 deficiency, or other laboratory abnormalities
- Suicidality, defined as active suicidal thoughts or ideation or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide
- Currently active major depression as determined by Beck Depression Inventory (BDI)-II score of >19
- Has a history or current diagnosis of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders.
- Clinically significant or unstable medical condition, including uncontrolled hypertension, or significant cardiac, pulmonary, hepatic, endocrine, or other systemic disease that in the Investigator's opinion may either put the participant at risk because of participation in the study, or influence the results, or impair the participant's ability to participate in the study
- Any disorder that could interfere with absorption, distribution, metabolism or excretion of drugs (e.g., small bowel disease, Crohn's disease, celiac disease or liver disease)
- Hospitalization or change of chronic concomitant medication within 8 weeks prior to baseline
- Body mass index (BMI) >38 kg/m2 or body weight <50 kg
- Has uncontrolled type 1 or type 2 diabetes. A subject with glycated hemoglobin (HbA1c) levels up to 7.5% can be enrolled if the Investigator believes the participant's diabetes is under control.
- Has moderate or severe renal disease.
- Has cancer or has had a malignant tumor (cerebral or systemic) within the past 3 years. (Participants with stable untreated prostate cancer or treated cutaneous squamous or basal cell carcinomas are not excluded)
- Presence or history of psychosis, including if induced by anti-parkinsonian medications at doses required to improve motor symptoms, or hallucinations not induced by medications
- Participant is currently pregnant, breast-feeding and/or lactating.
- History of alcohol or substance abuse or dependence within the past 2 years.
- Suspected or known allergy to any components of the study medication; Hypromellose Sodium lauryl sulfate, Lactose monohydrate, Croscarmellose sodium, Magnesium stearate.
- Clinically significant abnormalities in B12 or thyroid function tests (TFTs) that might interfere with the study
- Use of anticoagulants within 30 days or 5 half-lives (whichever is greater) prior to study drug administration and for the duration of the study
- Use of another investigational agent within 90 days or 5 half-lives (whichever is greater) prior to Screening and for the duration of the study
- Neutropenia defined as absolute neutrophil count of <1,500/microliter
- Thrombocytopenia defined as platelet count <100,000/microliter
- Clinically significant abnormalities in screening laboratory tests, including aspartate aminotransferase, alanine aminotransferase, total bilirubin, serum creatinine.
- Male participants with female partners of child-bearing potential who are unwilling or unable to adhere to contraception requirements specified in the protocol.
- Use of medications with potential drug-drug interactions within 2 weeks or 5 half-lives (whichever is greater) prior to study drug administration and for the duration of the study
- Any contraindication to DaTscan, including claustrophobia, the presence of metal (ferromagnetic) implants, a cardiac pacemaker, or allergy to iodine
- History of a seizure disorder, if stable on medication is acceptable
- An immediate family member (i.e., spouse, parent, child, or sibling, whether biological or legally adopted) of the Investigator, Sponsor or contract research organizations conducting the trial
- History of Covid-19 infection within 6 weeks prior to screening. Participants with unresolved symptoms of Covid-19 infection or ongoing cognitive or other deficits attributable to post-Covid-19, that may affect participant safety or interfere with cognitive assessments, based on the Investigator's clinical judgment.
- Unable to comply with the protocol procedures or any significant issue raised by the Investigator that may compromise participant safety or potentially interfere with study interpretation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 50 mg Active
50mg BID
|
50 mg capsules, oral administration
Other Names:
|
Experimental: 100mg Active
100mg BID
|
50 mg capsules, oral administration
Other Names:
|
Placebo Comparator: Matching Placebo
50 and 100 mg matching placebo
|
50 mg capsules, oral administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-emergent adverse events (TEAEs)
Time Frame: Up to 14 days after last dose
|
Safety
|
Up to 14 days after last dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the curve for the first 24 hours of dosing (AUC24h) and at steady state as determined by pharmacokinetic modeling
Time Frame: Up to 14 days after last dose
|
Total plasma concentration as determined by pharmacokinetic modeling
|
Up to 14 days after last dose
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate changes in α-synuclein
Time Frame: Up to 14 days after last dose
|
α-synuclein plasma concentration will be assessed for changes
|
Up to 14 days after last dose
|
Change from baseline dopamine transporter
Time Frame: Up to 3 days after last dose
|
Changes in dopamine transporter measured by single-photon emission computed tomography imaging
|
Up to 3 days after last dose
|
Assess changes in motor function
Time Frame: Up to 14 days after last dose
|
Change from baseline in motor aspects of experiences of daily living as measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS). The MDS-UPDRS is a clinical rating scale that assesses the symptomatic burden of Parkinson's Disease. The scale has four main sections, and each item is measured on a 5-point scale (0 to 4) where higher scores are associated with more disability. |
Up to 14 days after last dose
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Laurie Sanders, Ph.D, Duke University
Publications and helpful links
General Publications
- Ferreira DG, Temido-Ferreira M, Vicente Miranda H, Batalha VL, Coelho JE, Szego EM, Marques-Morgado I, Vaz SH, Rhee JS, Schmitz M, Zerr I, Lopes LV, Outeiro TF. alpha-synuclein interacts with PrPC to induce cognitive impairment through mGluR5 and NMDAR2B. Nat Neurosci. 2017 Nov;20(11):1569-1579. doi: 10.1038/nn.4648. Epub 2017 Sep 25.
- Corbett GT, Wang Z, Hong W, Colom-Cadena M, Rose J, Liao M, Asfaw A, Hall TC, Ding L, DeSousa A, Frosch MP, Collinge J, Harris DA, Perkinton MS, Spires-Jones TL, Young-Pearse TL, Billinton A, Walsh DM. PrP is a central player in toxicity mediated by soluble aggregates of neurodegeneration-causing proteins. Acta Neuropathol. 2020 Mar;139(3):503-526. doi: 10.1007/s00401-019-02114-9. Epub 2019 Dec 18.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ALX-923-107
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on BMS-9894923
-
CelgeneRecruitingProstatic NeoplasmsUnited States
-
China National Center for Cardiovascular DiseasesPeking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical...UnknownCoronary Artery EctasiaChina
-
Bristol-Myers SquibbCompletedHeart FailureUnited States
-
Bristol-Myers SquibbRecruitingProgressive Pulmonary FibrosisChina, United States, Japan, Korea, Republic of, Hungary, Canada, Argentina, Australia, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, India, Ireland, Italy, Mexico, Netherlands, Peru, Poland, Portuga... and more
-
Bristol-Myers SquibbRecruitingIdiopathic Pulmonary FibrosisChina, Taiwan, United States, Australia, Japan, Korea, Republic of, United Kingdom, Canada, Israel, Argentina, Austria, Belgium, Brazil, Chile, Colombia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Ireland, Italy, ... and more
-
Bristol-Myers SquibbCompleted
-
Bristol-Myers SquibbCompletedHeart Decompensation, AcuteUnited States
-
Dana-Farber Cancer InstituteStand Up To CancerActive, not recruitingLymphoma | Solid Tumor, Childhood | Brain Tumor, PediatricUnited States, Canada
-
Bristol-Myers SquibbCompletedHealthy VolunteersUnited States
-
Bristol-Myers SquibbCompletedHealthy ParticipantsUnited States